Expert Second Opinion — Investigators Discuss How They and Their Colleagues Navigate Emerging Clinical Research and Challenging Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes | Monday, August 9, 2021

• Introduction

• MODULE 1: Management of Newly Diagnosed Acute Myeloid Leukemia (AML) in Patients Ineligible for Intensive Induction Therapy — Richard M Stone, MD

• MODULE 2: Current and Emerging Strategies for Younger Patients with Previously Untreated AML — Harry Paul Erba, MD, PhD

• MODULE 3: Clinical Decision-Making for Patients Diagnosed with AML and an Actionable Mutation — Eunice S Wang, MD

• MODULE 4: Current and Future Treatment Considerations for Patients with Myelodysplastic Syndromes (MDS) — Krishna Gundabolu, MD

Beyond the Guidelines — Investigator Perspectives on the Management of Patients with Chronic Lymphocytic Leukemia | Tuesday, August 10, 2021

• Introduction

• MODULE 1: Therapeutic Algorithms for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL) — Susan O’Brien, MD

• MODULE 2: Spectrum, Frequency, Severity and Management of Toxicities Associated with Novel Agents and Regimens — Sonali M Smith, MD

• MODULE 3: Selection and Sequencing of Therapy for Patients with Relapsed/Refractory (R/R) CLL — Julie M Vose, MD, MBA

• MODULE 4: Novel Strategies Combining BTK and Bcl-2 Inhibitors in CLL — Matthew S Davids, MD, MMSc

• MODULE 5: Other Promising Investigational Agents and Strategies — Alexey V Danilov, MD, PhD

Cases from the Community — Investigators Discuss Emerging Research and Actual Patients with Multiple Myeloma

Thursday, August 12, 2021

• Introduction

• MODULE 1: Up-Front Management of Newly Diagnosed Multiple Myeloma (NDMM) — Robert Z Orlowski, MD, PhD

• MODULE 2: Selection and Sequencing of Therapies for Patients with Relapsed/Refractory (R/R) MM — Joseph Mikhael, MD

• MODULE 3: Chimeric Antigen Receptor (CAR) T-Cell Therapy in MM — Nina Shah, MD

• MODULE 4: Novel Agents and Strategies Under Investigation — Muhamed Baljevic, MD